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ABSTRACT 
Background:  Gynecomastia is defined as the presence of excessive breast tissue in males, 
which can appear unilateral or bilateral. Bilateral prepubertal gynecomastia in the absence of 
endocrine abnormalities is extremely rare, with only a few cases in literature. 
Case Presentation: A  46-year-old man  presented with a  2 years history of bilateral breast 
enlargement and pain. There is heartburn, shrinking testicles,  and  decreased sexual drive. 
Vital  examination showed  normal. BMI  : 24. 0 kg/m².  Head  dan neck: normal. On the 
chest both breasts are enlarged as avocados, palpable time around areola, chewy contingency, 
press pain, galactorrhea  negative. Lung and cast are  normal. In  the abdominal: hepar, lien 
and renal are not palpable, and ascites are not found. There is an atrophy of testicles.  Previous 
history of hepatic cirrhosis with Esophageal Varicose Veins caused by Hepatitis B. 
Laboratory examination  Estradiol 98.71 pg/mL (range: <62), Testosterone: 8.66 ng/mL 
(range: 3.0-10.6), LH5.53 mlU/mL, FSH 6.49 mlU/mL, Prolactin 5.08 ng/mL; Total T4 5.57 
ng/dL , TSH 1.84 μIU/mL. SGOT U/L 53, SGPT 71 U/L,  Hepatitis B (+), HBsAg Reactive 
S/CO 414.46; HBeAg: Non Reactive, HBV DNA Undetectable and Albumin 3.6 g/dL. 
Fibroscan:  Cirrhosis Hepatis. Abdominal ultrasound:  Cirrhosis Hepatis. Gastroscopy:  
Esophageal Varicose Veins (F1, LI, CB) + Pan Gastropathy.  
Conclusion: Reportedly A 46-year-old man presented with  gynaecomastia bilateral with  
Cirrhosis Hepatis Child Plug A, given conservative treatment with tamoxiphen for 1 month 
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ABSTRAK 
Latar Belakang: Ginekomastia didefinisikan sebagai terdapat jaringan payudara yang 
berlebihan pada laki-laki, yang dapat muncul unilateral atau bilateral. Ginekomastia 
prepubertal bilateral tanpa adanya kelainan endokrin sangat jarang terjadi, terdapat hanya 
beberapa kasus dalam literatur.  
Presentasi Kasus: Seorang pria berusia 46 tahun mengalami pembesaran payudara 
bilateral selama 2 tahun dan juga merasa sakit. Ada mulas, testis menyusut,  dan penurunan 
gairah seksual. Pemeriksaan vital menunjukkan normal. Didada kedua payudara membesar 
seperti buah alpukat, sekitar areola menghitam, konsistensi kenyal, nyeri, galactorrhea (-). 
Paru dan jantung. normal. Pada abdominal: hepar, lien dan ginjal tidak teraba, dan ascites 
(-). Ada atrofi testis. Sebelumnya riwayat sirosis hati dengan varises Esopagus yang 
disebabkan oleh Hepatitis B. IMT: 24,0 kg/m². Pemeriksaan laboratorium  Estradiol 98,71 
pg/mL  (rentang: < 62), testosteron: 8,66 ng/mL (rentang: 3,0-10,6), LH 5,53 mlU/mL, FSH 
6,49 mlU/mL, Prolactin 5,08 ng/mL; Total T4 5,57 ng/dL , TSH 1,84 μIU/mL. SGOT 53 U/L, 
SGPT 71 U/L,  Hepatitis B (+), HBsAg Reaktif S/CO 414,46; HBeAg: Non Reaktif, DNA 
HBV tidak terdeteksi dan albumin 3,6 g/dL.  Fibroscan: Cirrhosis Hepatis. USG Abdominal:  
Cirrhosis Hepatis. Gastroskopi:  Esophageal Varises (F1, LI, CB) + Pan Gastropati.  
Kesimpulan: Dilaporkan  Seorang pria  berusia 46 tahun dengan  ginaekomastia bilateral 
dan Cirrhosis Hepatis Child Plug A, diberikan pengobatan konservatif dengan tamoxiphen. 
Kata Kunci: Ginekomastia, Hirosis Hepatis, tamoxiphen 
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1 Introduction 
Gynecomastia is defined as the benign enlargement of the male breast, usually, a result of stromal 
proliferation and ductal hyperplasia. which can appear unilateral or bilateral. Bilateral 
gynecomastia is frequently found in the neonatal period, early in puberty, and with increasing 
age. Prepubertal bilateral gynecomastia in the absence of endocrine abnormalities is extremely 
rare, with only a few cases in literature.[1] 
Among the underlying causes, 3 groups of triggers are distinguished: physiologic, pathologic and 
pharmacologic/toxic. Pathophysiologically, female hormone imbalance has been shown to trigger 
glandular growth. This imbalance may in turn also be of pathologic or physiologic/idiopathic 
origin. There is strong evidence for the stimulating effect of estrogen on breast tissue 
development. Any disorder or medication leading to female hormone imbalance can trigger 
gynecomastia. Endogenous diseases like hyperthyroidism, chronic liver disease, primary or 
secondary gonadal failure, androgen resistance syndromes, medication, and lifestyle factors like 
drug abuse represent typical causes of gynecomastia [2]. Classification of gynecomastia [3]. 
Terdiri dari Grade I: minimal hypertrophy <250 g breast tissue; Grade II: moderate hypertrophy 
250–500 g breast tissue without ptosis; Grade III; severe hypertrophy >500 g breast tissue with 
grade I ptosis and Grade IV. severe hypertrophy with grade II–III ptosis. 
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In most cases, gynecomastia is caused by short- term hormonal fluctuations that limit themselves 
physiologically, which can occur neonatally, during puberty, and in elderly men. In the neonatal 
period, a preliminary physiologic bilateral mammary glandular swelling is triggered by maternal 
placental estrogens and resolves within a few weeks after birth. In adolescence, physiologic 
pubertal gynecomastia can develop and may last up to 6 months. This is triggered by a relative 
estrogen excess, mainly due to peripheral aromatization of the testicular and adrenal androgens. 
Testicular testosterone production increases in late puberty and leads to a spontaneous regression 
of the gynecomastia [4]. Due to a decrease in testosterone production and an increase in sex 
hormone-binding globulin, gynecomastia is also common in elderly men. 
2 Case report:  
An 46-year-old-man presented with a 2 years history of bilateral breast enlargement and pain. 
There is heartburn, shrinking testicles, decreased sexual drive, and no confidence. No history or 
sign of galactorrhea existed. Physical examination showed normal. BMI: 24.0 kg/m². Head dan 
Neck: normal. On the chest, both breasts are enlarged as avocados, palpable time around areola, 
chewy contingency, press pain, galactorrhea  negative. Lung and cor is normal. In  the abdominal: 
hepar, lien and renal is not palpable, and ascites are not found.  gender:  Male and there is atrophy 
of testicles. Previous history of hepatic cirrhosis with Esophageal Varicose Veins caused by 
Hepatitis B. 
Laboratory Results 
Urine, blood sugar and cholesterol are normal. Estradiol 98.71 pg/mL (high), Testosterone: 8.66 
ng/mL (high), LH 5.53 mlU/mL, FSH 6.49 mlU/mL, Prolactin 5.08 ng/mL; Total T4 5.57 ng/dL 
, TSH 1.84 μIU/mL. SGOT 53 U/L, SGPT 71 U/L, Hepatitis B (+), HBsAg Reactive S/CO 
414.46; HBeAg: Non Reactive, HBV DNA Undetectable and Albumin 3.6 g/dL. 
Mammae Ultrasound: Both mamae  enlarge  asymmetrically, left is larger than the right. Both 
mammae consist of fatty and fibroglandural components, but are more dominant fibroglandular 
in both mamaes especially the leftones (fig 1). There is no visible enlargement of the lymph nodes 
on both axillas. Impressions: Gynecomastia on the right and left mammae. Fibroscan: Sirosis 
Hepatis. Abdominal ultrasound:  Hepar,  irreguler surface, blunt edge, shrinking size, coarse 
homogeneous parenym. Conclusion:  Cirrhosis Hepatis. Gastroscopy: Esophageal Varicose Veins 
(F1, LI, CB) + Pan Gastropathy. 
Diagnosis: gynaecomastia in the right and left mammae and Cirrhosis Hepatis Child Plug A, 
Hepatitis B, Varicose Veins of the Oesophagus. Diagnosis is bilateral gynaecomastia  with  

















Figure 1  
3 Discussion 
Gynecomastia correlated directly with body mass index (BMI) and with age. Individuals with 
more severe cirrhosis usually are very thin, although the BMI may be increased owing to the 
pres¬ ence of ascites or peripheral edema. It has been suggested that gynecomastia in all subjects 
is the result of a reduced circulating testosterone concentration, an elevated estrogen 
concentration, or both resulting in an increase in the estrogen-testosterone ratio.[5] Men with 
cirrhosis have decreased production of testosterone, increased production of androstenedione, 
increased conversion of androstenedione to estrone, and increased levels of sex hormone-binding 
globulin.[6] same in the control subjects and those with cirrhosis, even though the estrogen-
testosterone ratios were much lower in the controls. 
In the case of true gynecomastia, clinical examination by palpation followed by ultrasound 
examination and if necessary mammography reveal glandular tissue. Palpation of the breast 
should be able to clinically distinguish fatty tissue from glandular tissue and should include a 
more detailed assessment of the breast such as ptosis, skin excess, and nipple retraction. The 
physical examination should also extend to testicular palpation in order to detect testicular 
changes and atrophies at an early stage and to pave the way for further diagnostic measures. In 
particular, in young men with a negative history and bilateral gynecomastia, the incidence of 
testicular endocrine tumors is showing a significant increase [7]. The diagnosis of gynecomastia 
must be confirmed histologically by a sonographically, showing a 90% sensitivity and specificity 
[8]. Standard diagnostics include laboratory tests like human choric gonadotropin, luteinizing 
hormone, thyroid-stimulating hormone, testosterone, and estradiol [9].  
Conservative and Surgical Management 
he therapy of gynecomastia may be conservative or surgical. Conservative therapy must be based 
on the cause of the gynecomastia. Self-limiting physiologic forms of gynecomastia should be 
followed up until resolved. In the case of persistence or progress, if necessary, laboratory 
diagnostic tests should be repeated to detect hormonal processes as quickly as possible. A 
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conservative therapy option is the administration of serum estrogen receptor modulators such as 
tamoxifen. Tamoxifen at a daily oral dose of 20 mg for up to 3 months has shown good results in 
randomized and non-randomized trials. and post-traumatic deep vein thrombosis, are rarely 
reported [9]. The use of anastrozole, an aromatase inhibitor, is not recommended as it did not 
show more effectiveness than placebo in boys with pubertal gynecomastia [11]. If conservative 
pharmacologic therapy attempts are to be considered, it should be noted that hypertrophic 
glandular tissue becomes irreversibly fibrotic by way of remodeling after no more than 12 months. 
This fibrous tissue cannot be removed conservatively and proceeding with surgical management 
must be considered.[12] The indication for surgical therapy is based on the patient’s suffering, 
including psychosocial stress and pain as well as cosmetic distortion [13]. The aim of all surgical 
procedures is to remove the hypertrophic fibrotic glandular tissue and to reestablish the male 
breast shape. Therapeutic techniques include breast tissue resection, liposuction, and combined 
techniques. From stage III onwards, reduction mammoplasty should be explored taking into 
Regression of gynecomastia is seen in up to 80% of patients [14]. However, the available data on 
tamoxifen stems from few studies with very small case numbers [15]. Adverse side effects, 
including epigastric distress consideration the extent of the hypertrophic tissue and the expertise 
of the surgeon [16]. For milder forms, the periareolar edge cut to the mastectomy can suffice. 
4 Conclusion. 
Reportedly A 46-year-old man presented with  gynaecomastia bilateral with  Cirrhosis Hepatis 
Child Plug A, given conservative treatment with tamoxiphen for 1 month 
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